Company patents

Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. demonstrates a strong, albeit shifting, focus within pharmaceutical innovation, with Heterocyclic Compounds representing a dominant 82.5% of its portfolio, despite a -36.4% decline in patent filings so far in 2026. While Therapeutic Activity also shows a significant presence at 61.9% of the portfolio, the company has surprisingly shown an emerging focus on Pharmaceutical Preparations, which experienced a 100.0% year-over-year growth in 2024 and a 25.0% growth in 2025, indicating a strategic pivot towards drug formulation and delivery.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

63 US filings (since 2023) · 4 categories · 8 themes

Targeted Small Molecule Therapeutics

Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.

Heterocyclic Compounds (Pharma)Pharmaceutical Preparations
Who else files here? →
52since 2023
0.0%YoY
Targeted Protein Degradation

Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.

Heterocyclic Compounds (Pharma)
Who else files here? →
43since 2023
+33.3%YoY
Nucleic Acid-Based Therapies

Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.

Therapeutic Activity (Pharma)Pharmaceutical Preparations
Who else files here? →
30since 2023
-12.5%YoY
Antibody Engineering & Therapeutics

Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.

Therapeutic Activity (Pharma)Pharmaceutical Preparations
Who else files here? →
10since 2023
-66.7%YoY
Advanced Cell & Gene Therapies

Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.

Pharmaceutical Preparations
Who else files here? →
7since 2023
+150.0%YoY
API Solid Form Engineeringfiltered

Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.

Heterocyclic Compounds (Pharma)General Organic Chemistry Methods
Who else files here? →
2since 2023
+100.0%YoY
Chemical Synthesis of Drug Intermediates

Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.

Heterocyclic Compounds (Pharma)
Who else files here? →
1since 2023
new
Immune Checkpoint Modulation

Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.

Therapeutic Activity (Pharma)
Who else files here? →
1since 2023
n/a

Patents

Page 1 of 1